Sweden's Stille Q2 sales jump 50% on improved product availability

Stille AB

23/07/2026 07:14

((This story was generated using AI and automation, please see
disclaimer https://bit.ly/rtrsnai))
Overview
    * Sweden surgical instruments maker's Q2 net sales rose 50% yr/yr, organic growth 27%
    * Gross margin fell to 48.4% from 52.1% a year earlier
    * Company says growth driven by improved product availability and M&A focus

Outlook
    * Stille says product availability continues to improve, supporting demand for its products
    * Company is evaluating additional acquisitions and strengthening its team for M&A activities

Result Drivers
    * PRODUCT AVAILABILITY - Co said improved product availability helped drive demand for its products
    * M&A FOCUS - Co said it is strengthening its team to accelerate M&A activities and is evaluating additional acquisition opportunities

Company press release:  ID:nMFN82V6RF 
Key Details
 Metric    Beat/Mis  Actual    Consensu
           s                   s
                               Estimate
 Q2        Beat      SEK       SEK
 Revenue             186.90    176.50
                     mln       mln (2
                               Analysts
                               )
 Q2                  SEK        
 Adjusted            36.50     
 EBITDA              mln       
 Q2                  SEK        
 Adjusted            27.40     
 EBIT                mln       
 Q2 EBIT             SEK        
                     27.40     
                     mln       
 Q2                  SEK        
 EBITDA              36.50     
                     mln       
 Analyst Coverage
    * The one available analyst rating on the shares is "buy"
    * The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"
    * Wall Street's median 12-month price target for Stille AB is SEK279.00, about 7.3% above its July 22 closing price of SEK260.00
    * The stock recently traded at 24 times the next 12-month earnings vs. a P/E of 21 three months ago

Reuters Recommended Reads
    * July 21 - Sweden's MedCap Q2 net sales rise 16% on organic growth and acquisitions
    * July 21 - Sweden's Asker Healthcare Q2 profit jumps on increased scale
    * July 23 - Sweden's Mentice Q2 sales rise, EBITDA turns positive on strategic initiatives

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)